Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism DYRK2 inhibitors(dual specificity tyrosine phosphorylation regulated kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC18H20N2O2S |
InChIKeyZFOMCSNUEHMROO-UHFFFAOYSA-N |
CAS Registry184582-62-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Preclinical | US | 21 Nov 2019 | |
Triple Negative Breast Cancer | Preclinical | US | 21 Nov 2019 |